此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

To Identify if a COPD Self-management App Can Safety and Appropriately Identify When Patients Are Not on the Best Medication Plan for Their COPD Symptoms and Support Their COPD Management. (mySmartCOPD)

2026年8月28日 更新者:University of Southampton

To Explore the Safety and Clinical Efficacy of a Treatment Realignment Algorithm Using Data From a Digital Self-management Application for Patients With COPD

Although COPD cannot be cured, managing COPD can help reduce symptoms control, slows progression of the disease, and may improve the quality of life. Management of COPD becomes less effective when healthcare professionals fail to prescribe appropriate inhaled therapies, due to poor adherence to evidence-based guidelines and underdiagnosis, or when patients fail to adhere to prescribed treatment regimens.

my mhealth has developed an app called myCOPD to allow patients to record their COPD symptoms and medications, which in term supports them with their COPD. This app is now used by COPD patients across the UK, via a prescription from their healthcare professionals. my mHealth has now developed a research app MMH-LAB1 which, in the intervention arm, includes an algorithm to assist patients with understanding their level of symptom burden according to the severity of their daily symptoms and exacerbation risk. The algorithm then analyses current patient prescribed inhaled medication against those recommended by the GOLD 2023 report and informs the patient via the MMH-LAB1 app as to whether their medication needs to be changed by their healthcare provider. This trial will explore whether the introduction of the algorithm within the MMH-LAB1 app can be used as a safe, effective and acceptable tool to assist patients to achieve optimal guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients.

Participants will be randomised to the MMH-LAB1 app - control arm (MMH-LAB_Control_1 where participants just record COPD symptoms and medications), or to the MMH_LAB1 app - intervention arm (MMH-LAB1_Test_1 where participants record their COPD symptoms and medication plus receiving information from the algorithm, as to whether their medications are in guidance or not, and if not, be notified to visit their healthcare professional.

研究概览

地位

招聘中

条件

详细说明

This study is an open-label randomised control trial with inbuilt pilot phase and qualitative sub-study:

Phase 1 (pilot - 50 participants): Interim futility analysis on adherence to intervention advice Phase 2 (efficacy - 746 participants (including pilot phase participants): Safety acceptability and efficacy of intervention. This includes the qualitative sub study 15-20 participants (from the 746 Phase 2 participants).

Qualitative Sub-study: Acceptability of the intervention (15-20 intervention participants)

This trial will explore whether the introduction of the treatment realignment algorithm can be used as a safe, effective and acceptable tool to assist patients to achieve optimal, guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients. To assess effect of the intervention on patients' symptom control, including exacerbation frequency and patient wellness scores.

Main objectives

  • To understand the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
  • To assess the levels of app usage and engagement
  • To assess patients' experience of using the intervention

Study Design:

Open-Label Randomised Control Trial with inbuilt pilot phase Qualitative Sub study:

Phase 1 (Pilot): Interim futility analysis on adherence to intervention advice Phase 2 (Efficacy): Safety, acceptability and efficacy of intervention Qualitative Sub-study: Acceptability of the intervention.

The research question is to explore the safety and efficacy of the treatment re-alignment algorithm as part of a digital self-management application (app) in patients with COPD.

研究类型

介入性

注册 (估计的)

746

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • England
      • Southampton、England、英国、SO16 6YD
        • 招聘中
        • University Hospital Southampton
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  1. Adult patients over 18 years of age and able to give informed consent
  2. A clinical diagnosis of COPD (all patients registered on the app have a confirmed diagnosis of COPD confirmed by their clinician before being prescribed the app).
  3. A registered and activated user of the myCOPD app
  4. One or more CAT questionnaire completed on the myCOPD app in the last 12 months
  5. One or more exacerbation form completed on the myCOPD app in the last 12 months CTU/FORM/5321 - CIP template for Clinical Investigations of Medical Devices, Version 1 14-DEC-2023 mySmartCOPD Clinical Investigation Plan v1 25-FEB-2025 Page 25 of 53
  6. One or more COPD medication diary completed on the myCOPD app in the last 12 months
  7. Classified appropriately into 3 groups:

    (A) Few symptoms (CAT <10, 0 or 1 moderate exacerbations) (B) Many symptoms (CAT ≥10, ≥0 or 1 moderate exacerbations) (C)Exacerbators (≥2 moderate or ≥1 severe exacerbation independent of CAT)

    Exclusion Criteria:

  8. Cannot read or write in English as required to understand the trial materials and provide the trial data.
  9. Has not opted in to the research agreement via MyCOPD

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:MMH-LAB1 Control This arm is based on the original COPD app the participants already use
Participants for this study are already users of a COPD self management app. This arm is a replica of this app, with additional questionnaires built in
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review
实验性的:MMH-LAB1 Test This arm is based on the original COPD app the participants use plus an algorithm
Participants for this study are already users of a COPD self management app. This arm is a replica of this app, with additional questionnaires built in plus an algorithm which identifies, based on the symptoms and medication reported onto the app by the participant, whether they are on the correct medication or not. If not, the app will generate a notification and inform the participant that they need to approach their healthcare provider and inform them of this and that they need a medication review.
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To determine the safety, acceptability and efficacy of a digital treatment guidance algorithm for inhaled treatment in patients with COPD. The intention is to measure the impact of the algorithm in prompting patients to achieve optimal management, and t
大体时间:6 months
Proportion (measured in %) of participants receiving guideline adherent treatment at Baseline and trial completion (Month 6). Range 0%-100%.
6 months

次要结果测量

结果测量
措施说明
大体时间
To assess effect of intervention on exacerbation frequency and patient wellness scores
大体时间:6 months

• Change in COPD Assessment Test (CAT) score between Baseline and trial completion (Month 6)

CAT test results 0 minimal symptom impact - Best and 40 maximum symptom impact

All will be described in terms of:

  • Mean and SD
  • Median and range and will be reported as descriptive stats
6 months
To assess effect of the intervention on patients' adherence to guideline mandated treatment
大体时间:6 months

- Rate of indication of algorithm to change treatment (0 times to 150 times)

• Rate if change in response to treatment change indication (0 times to 150 times)

All measured via frequency and percentage and description of change.

The combination of measurements will be reported as descriptive stats

6 months
To understand the utility of the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
大体时间:6 months

- % Patients receiving guideline adherent treatment at Baseline and trial completion (Month 6). 100% good. 0 % bad.

Above described qualitatively and in terms of % and frequency

6 months
To assess the levels of app algorithm usage and engagement
大体时间:6 months

-Frequency of app engagement

  • Rate of completion of endpoint data
  • Resource requirement to allow patients to act on intervention information

Measured by frequency (numbers of participant who completed everything) % (0% of expected use bad and 100% of expected use good). This will be reported as descriptive stats.

6 months
To understand patients' experience of using the intervention
大体时间:3-6 months - interviews. 6 months - feedback questionnaire

This section relates to the qualitative sub-study and will look at the following:

- Patient experience and patient and patient advocate feedback on experience of using app

• Patient satisfaction Rating using the Patient

Using feedback questionnaire at month 6 and qualitative interviews as part of the sub -study

  • Qualitative data will be thematically analysed and written up in a report. Tables will be produced outlining key themes and illustrative quotes
  • Frequency and percentage.
  • Means and standard deviations.
  • Statistical tests may be performed to explore any difference in experience of using the intervention relative to cohort groupings

This will be reported in a separate analysis document using qualitative research analysis and reporting techniques and norms

3-6 months - interviews. 6 months - feedback questionnaire
To assess the safety of the algorithm
大体时间:6 months

• Rate of algorithm inappropriately firing notifications

This is data collected via MMHLAB apps and qualitatively via patient advocate.

  • Frequency and percentage. (0 times good, not maximum time - But anything over 0 is bad)
  • Means and standard deviations.
6 months
To assess the change in frequency of exacerbations
大体时间:6 months
Frequency of exacerbation between Baseline and trial completion (Month 6) • Frequency and percentages (for number of exacerbations) Frequency will be measured from 0-150 with 0 being optimal. This will be reported as descriptive stats.
6 months
To assess the change in Quality of Life between baseline and 6 months
大体时间:6 months
Change in Quality of Life. Ratings measured using EQ-5D questionnaire between Baseline and trial completion (Month 6). All will be described in terms of: • Mean and SD • Median and range. Score 11111 will be classed as full health and 55555 will be classed worst health. This will be reported as descriptive stats
6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月8日

初级完成 (估计的)

2026年9月1日

研究完成 (估计的)

2026年9月1日

研究注册日期

首次提交

2025年5月7日

首先提交符合 QC 标准的

2026年8月28日

首次发布 (实际的)

2026年9月1日

研究记录更新

最后更新发布 (实际的)

2026年9月1日

上次提交的符合 QC 标准的更新

2026年8月28日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 355764
  • AI_Award02200 (其他赠款/资助编号:UK - National Institute for Health and Care Research)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅